

In search for vaccinations without cold storage - CTO Orest Lastow in MEDTECH Outlook

After an unprecedented year in the covid-19 pandemic, the challenges with vaccines requiring cold storage, from refrigeration to ultra-cold storage has become public knowledge. Dr Orest Lastow, founder and CTO of Iconovo AB (publ) that develops complete inhalation products, shares his thinking about a better vaccine solution in MEDTECH Outlook – to inhale a stable dry powder formulation using a single-use inhaler like ICOone from Iconovo.

To read more:

https://www.medicaltechoutlook.com/vp/iconovo/2021_-search_for_vaccinations_without_cold_storage_/

ICOone has already been selected by Monash University for its suitability as a single-use inhaler of oxytocin replacing injectable oxytocin in resource-constrained countries.

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled drugs such as vaccines.

By working with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thereby eliminating the complex and costly early stages of the development phase. Iconovo licenses its patented products to customers and offers a faster way to the inhalation market with lower risk and at a lower cost.

More information about the company can be found at www.iconovo.se.

Iconovo is based in Lund and its share (ticker ICO) is listed on Nasdaq First North Growth Market, Stockholm since April 6, 2018. The Company's Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm, phone +46 8 463 80 00, email: certifiedadviser@penser.se.

Attachments

[In search for vaccinations without cold storage - CTO Orest Lastow in MEDTECH Outlook](#)